Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study - 05/10/22

Abstract |
Objective |
COVID-19 due to SARS-CoV-2 virus is a new cause of severe acute respiratory syndrome (SARS). Little is known about the short-term cognitive prognosis for these patients. We prospectively evaluated basic cognitive functions shortly after care in the intensive care unit (ICU) and three months later in post-ICU COVID-19 patients.
Material and methods |
We performed a prospective single-center study in our institution in Paris. Patients with SARS-CoV-2 SARS were prospectively recruited via our ICU. Patients were evaluated using standardized cognitive tests at baseline and at three months’ follow-up. Our primary endpoint was the evolution of the following five global tests: MMSE, FAB, oral naming test, Dubois five words test and MADRS.
Results |
We explored 13 patients at baseline and follow-up. All patients had cognitive impairment at baseline but they all improved at three months, significantly on two of the five global tests after Bonferroni correction for multiple testing: MMSE (median 18 (IQR [15–22]) and 27 (IQR [27–29]) respectively, P=0.002) and FAB test (median 14 (IQR [14–17]) and 17 (IQR [17,18]) respectively, P=0.002).
Conclusions |
We report here the first longitudinal data on short-term cognitive impairment after intensive care in COVID-19 patients. We found acute and short-term cognitive impairment but significant improvement at three months. This pattern does not seem to differ from other causes of post-intensive care syndrome.
Le texte complet de cet article est disponible en PDF.Keywords : Cognitive disorder, COVID-19, Critical care syndrome, Executive function, SARS-CoV-2
Plan
Vol 178 - N° 8
P. 802-807 - octobre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.